1. Acute illness at the time of screening <br/ >2. History of laboratory confirmed COVID-19 <br/ >3. History of allergic reactions after previous vaccinations including primary vaccination for COVID-19 <br/ >4. Have any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw <br/ >5. Suspected or known current alcohol or drug dependence <br/ >6. Chronic administration of immunosuppressant or other immune-modifying drugs within three months prior to the study vaccination or planned use throughout the study period <br/ >7. Administration of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months or planned use throughout the study period <br/ >8. Administration of any vaccine within 28 days prior to enrolment in the study or planned administration of any vaccine for until 28 days after study vaccination <br/ >9. Prior receipt of a booster dose of COVID-19 vaccine <br/ >10. Pregnant or breast-feeding <br/ >11. Acute or chronic, clinically significant systemic disorders <br/ >12. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the participant in the study or make it unlikely that the participant could complete the protocol

1. Acute illness at the time of screening <br/ >2. History of laboratory confirmed COVID-19 <br/ >3. History of allergic reactions after previous vaccinations including primary vaccination for COVID-19 <br/ >4. Have any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw <br/ >5. Suspected or known current alcohol or drug dependence <br/ >6. Chronic administration of immunosuppressant or other immune-modifying drugs within three months prior to the study vaccination or planned use throughout the study period <br/ >7. Administration of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months or planned use throughout the study period <br/ >8. Administration of any vaccine within 28 days prior to enrolment in the study or planned administration of any vaccine for until 28 days after study vaccination <br/ >9. Prior receipt of a booster dose of COVID-19 vaccine <br/ >10. Pregnant or breast-feeding <br/ >11. Acute or chronic, clinically significant systemic disorders <br/ >12. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the participant in the study or make it unlikely that the participant could complete the protocol